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Abstract. The receptor activator of nuclear factor-kB (RANK) gene is found in both human and 17 
murine mammary epithelial cells and in human cancer cell lines. We analyzed RANK expression 18 
in normal and proliferative canine mammary tissue samples (n = 47) and cell lines (n = 10), and 19 
identified its expression in epithelial cell populations. The correlation of RANK protein with 20 
clinicopathologic parameters was also studied. A double immunohistochemical method using 21 
RANK and p63 antibodies was applied to 33 tissue samples to analyze RANK protein expression 22 
and its possible co-expression with p63 protein, the latter used to identify myoepithelial (ME) 23 
cells (p63-positive) or luminal epithelial (LE) cells (p63-negative). RANK protein expression 24 
was found in ~75% of the tissue samples analyzed, at a similar level in all of the histologic types 25 
studied: dysplasias (4 of 4, 100%), malignant tumors (13 of 17, 76%), normal glands (12 of 17, 26 
70%), and benign tumors (6 of 9, 67%). ME and LE cells expressed RANK protein at a similar 27 
level. A higher level of RANK protein expression was found in older animals (≥10 y, p = 0.027). 28 
Quantitative RT-PCR was applied to 6 ME (1 normal and 5 neoplastic) and 4 LE (1 normal and 3 29 
neoplastic) primary cell lines. The RANK gene was found at similar expression levels in all 30 
canine mammary ME and LE cell lines studied. We found RANK expression in normal, 31 
dysplastic, and neoplastic canine mammary tissues and cell lines, in both ME and LE cell 32 
populations. 33 
 34 
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The receptor activator of nuclear factor-kB (RANK) is a receptor of the tumor necrosis factor 38 
(TNF) family of cytokines, which upon binding to its ligand (RANKL) transduces a variety of 39 
survival, proliferation, differentiation, and migration signals.
12
 RANK and RANKL play key 40 
roles in bone remodeling and bone-related lesions.
20
 RANK is expressed primarily on the surface 41 
of osteoclasts,
20
 in dendritic cells,
19
 in T-cells,
19
 and in mammary epithelial cells.
4
 Furthermore, 42 
RANK protein is critical for mammary gland development.
4
 RANK gene expression has been 43 
analyzed in both normal and neoplastic mammary gland specimens and their metastases in 44 
humans and murine species,
2,9,16
 and in several human breast cancer cell lines.
2,9
 At the time of 45 
writing, we found no studies on RANK expression in the canine mammary gland. 46 
Mammary gland tumors are the most common neoplasms in female dogs (25–50% of all 47 
tumors in intact female dogs).
10
 Ducts and alveoli of normal glands are composed of 2 cell 48 
layers, an inner or luminal epithelial (LE) cell layer and an outer layer of myoepithelial (ME) 49 
cells.
6
 Although frequently presented as a spontaneous model of breast cancer, mammary 50 
carcinomas in the female dog have lower biological aggressiveness than those in women. This 51 
fact has been linked, at least in part, to the higher participation of ME cells in canine mammary 52 
tumors, which are considered to be natural paracrine suppressors of invasion and metastasis.
18
 53 
We analyzed RANK protein expression in normal, hyperplastic, and neoplastic canine 54 
mammary tissue samples by immunohistochemistry, and RANK gene expression in canine cell 55 
lines by quantitative reverse transcription PCR (RT-qPCR). In addition, we determined RANK 56 
expression in the ME and/or LE cell populations specifically. Thirty-three mammary gland 57 
biopsies or mastectomy specimens from 26 female dogs were collected from the archives of the 58 
Department of Comparative Pathology of the University of Córdoba (Spain). Tissue samples had 59 
been fixed in 10% neutral-buffered formalin for 24–72 h, embedded in paraffin, and processed 60 
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routinely. Age of dog, tumor size, histologic classification,
7
 and histologic grade of malignant 61 
tumors
13
 were evaluated. The 33 specimens comprised 3 normal glands, 4 dysplastic glands 62 
(including ductal hyperplasia, lobular hyperplasia, and duct ectasia), 9 benign tumors, and 17 63 
malignant tumors. The latter had been classified into histologic grade 1 (n = 9), grade 2 (n = 7), 64 
and grade 3 (n = 1). Normal tissue comprised the 3 normal mammary gland specimens, plus 65 
unaltered, normal mammary gland tissue surrounding tumor specimens in 14 of the cases. For 66 
immunohistochemistry (IHC), all cases were analyzed using a double-immunostaining method 67 
according to the manufacturer’s protocol (EnVision doublestain system, Dako, Glostrup, 68 
Denmark). Two primary antibodies were used: 1) anti-RANK (Polyclonal IgG antibody, Santa 69 
Cruz Biotechnology, Heidelberg, Germany) diluted 1:90, and 2) anti-p63 (monoclonal [clone 70 
4A4] isotype IgG2 antibody, Santa Cruz Biotechnology) diluted 1:100 and selected as the marker 71 
of ME cells.
6
 A commercial antibody diluent (Dako) was used throughout. RANK 72 
immunostaining was developed in fast red (Permanent red substrate-chromogen, liquid, Dako), 73 
and p63 immunostaining was developed with 3,3’-diaminobenzidine tetrahydrochloride (DAB) 74 
brown (Dako). As negative control, primary antibodies were replaced by the immunoglobulin 75 
fraction of serum from non-immunized rabbits and mouse IgG2 (Dako), respectively, diluted as 76 
for the primary antibodies. As positive controls, canine lymph node and normal skin were used 77 
for RANK and p63 antibodies, respectively. Furthermore, tissue-associated macrophages were 78 
used as internal positive controls for RANK antibody. 79 
Immunolabeled slides were randomized and masked for blind examination, which was 80 
performed independently by 2 observers (R Sánchez-Céspedes, J García-Macías). When there 81 
was disagreement (<5% of slides), a consensus between the 2 observers was reached using a 82 
multi-head microscope. RANK scoring was rated by comparing labeling intensity with that of 83 
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the internal positive control (tissue-associated macrophages) as follows: absent (RANK0), 84 
positive but less intense than internal control tissue (RANK1+), positive and equal to the internal 85 
control tissue (RANK2+), and positive but more intense than the internal control tissue 86 
(RANK3+). Cells were considered to be p63+ when they displayed brown nuclear labeling and 87 
p63-negative (p63–) when they lacked brown nuclear labeling. For quantification, images were 88 
captured (40× microscope objective) from 10 randomly selected neighboring, non-overlapping 89 
fields. A sample was considered to be RANK+ when immunostaining intensity was RANK2+ or 90 
RANK3+ in >50% of cells.
16
 The co-expression of RANK and p63 antigens was classified as 91 
follows: p63+/RANK–, p63+/RANK+, p63–/RANK–, and p63–/RANK+. The number of cells 92 
belonging to each group was determined by 2 independent observers (R Sánchez-Céspedes, J 93 
García-Macías) with a digital pen tablet (Volito 2, Wacom Europe, Germany), and the 94 
percentages were calculated using Image-Pro Plus 4.5 (Media Cybernetics, Rockville, MD). 95 
Three fresh samples of mammary tumors and 1 of normal mammary gland (Table 1) were 96 
collected from 3 female dogs during surgery at the Department of Veterinary Sciences, 97 
University of Turin, Italy (cases 1–3). These fresh samples were processed to obtain primary ME 98 
and LE cell lines according to our method proposed previously.
15
 Thus, the magnetic-activated 99 
cell sorting (MACS) technique based on the binding of antibody-coated magnetic microspheres 100 
to Thy1 (ME cell–specific surface antigen) using an anti-Thy1 antibody was used to purify and 101 
isolate canine mammary ME cells (positive selection) or LE cells (negative selection).
3,15
 102 
Afterward, immunocytochemistry using typical ME or LE lineage markers was carried out to 103 
confirm the phenotype of the cells in primary culture.
15
 All 4 tissues were also processed 104 
routinely and stained for histologic classification
7
 and immunophenotyping using the ABC 105 
method (Avidin–biotin–complex, Vector Laboratories, Orton Southgate, Peterborough, UK), 106 
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with anti-cytokeratin (CK)14 polyclonal rabbit antibody (Covance Research, Munich, Germany; 107 
diluted 1:500) for ME cells and anti-CK8/18 antibody (clone NCL-5D3, isotype IgG1 antibody, 108 
Euro-Diagnostica, Malmö, Sweden; diluted 1:20) for LE cells.
15
 Furthermore, in order to 109 
increase the number of cell lines studied, 2 ME cell lines characterized previously by our 110 
research group
15
 were also used: CmME-K1 (complex carcinoma) and CmME-K2 (simple 111 
tubulopapillary carcinoma). 112 
For RT-qPCR expression analysis, total RNA was obtained from ME and LE cell lines, 113 
and 1 µg of total RNA was reverse-transcribed using commercially available reagent sets 114 
(QiantiTec reverse transcription kit, Qiagen, Hilden, Germany). Quantitative RT-PCR was used 115 
to measure the quantity of RANK relative to the quantity of glyceraldehyde-3-phosphate 116 
dehydrogenase (GAPDH) and hypoxanthine phosphoribosyl transferase (HPRT) messenger 117 
(m)RNA using commercially available reagent sets (IQ SYBR Green supermix and IQ 5 118 
detection system, Bio-Rad, München, Germany). GAPDH and HPRT were used as housekeeping 119 
genes. Primer sequences were designed using Primer Express v.2.5 (Thermo Fisher Scientific, 120 
Waltham, MA): RANK, 5’-ATGTGGTTTGTAGTTCTTCTC-3’ (forward), 5’-121 
ACTCCTTATTTACACTTAGG-3’ (reverse); GAPDH, 5’-GGCACAGTCAAGGCTGAG-3’ 122 
(forward), 5’-CCAGCATCACCCCATTTGAT-3’ (reverse); and HPRT, 5’-123 
CACTGGGAAAACAATGCAGA-3’ (forward), 5’-ACAAAGTCAGGTTTATAGCCAACA-3’ 124 
(reverse). Real-time PCR parameters were: cycle 1, 95°C for 30 s; cycle 2, 95°C for 10 s, 60°C 125 
for 30 s for 40 cycles. The level of gene expression was calculated using a relative quantification 126 
assay corresponding to the comparative threshold cycle (Ct) method: the amount of target, 127 
normalized to the endogenous housekeeping genes and relative to the calibrator (control sample), 128 
Page 7 of 18 
was then transformed by 2
-ΔΔCt
 (fold increase), where ΔΔCt = ΔCt (sample) – ΔCt (control); ΔCt 129 
is the Ct of the target gene subtracted from the Ct of the housekeeping genes. 130 
Immunohistochemical and clinicopathologic results were grouped into contingency tables 131 
and analyzed using the Fisher exact test; p ≤ 0.05 was considered statistically significant. Data 132 
were analyzed with GraphPad Prism v.4.0 (GraphPad Software, San Diego, CA). 133 
RANK labeling was seen in the cytoplasm of epithelial ductal and alveolar cells of 134 
normal, dysplastic, and neoplastic glands, osteoclasts of mixed tumors, and tissue-associated 135 
macrophages within and around the tumors. The latter 2 cell types were used as internal positive 136 
controls of RANK labeling. Cytoplasmic staining was diffuse and an apical/luminal RANK 137 
labeling pattern was also observed in some ductal and alveolar cells. 138 
RANK expression varied with histologic classification, although differences were not 139 
statistically significant (Table 2). Thus, 12 of 17 (70%) normal, all (4 of 4, 100%) dysplastic, and 140 
19 of 26 (73%) tumorous mammary glands were classified as RANK+ cases (Table 2). The 141 
single simple adenoma studied (composed of LE cells exclusively) was classified as RANK– 142 
(Fig. 1), whereas 1 of 2 (50%) complex adenomas was negative and 5 of 6 (83%) benign mixed 143 
tumors were considered RANK+ cases (Fig. 2). The majority of simple and complex carcinomas 144 
(80% and 89%, respectively) and a single (1 of 3, 33%) mixed carcinoma were classified as 145 
RANK+ cases. 146 
The median percentage of RANK+ cells found in RANK+ cases was similarly high in all 147 
groups (93% in normal and 80% in dysplastic glands; 76% in benign and 71% in malignant 148 
tumors; Table 2). The median percentage of both ME and LE cells expressing RANK was 149 
similar in the different histologic types of samples studied (Table 2). 150 
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In both normal and dysplastic glands, RANK+ cells were found in the LE cells of the 151 
ductal and lobular system with both diffuse and apical/luminal staining patterns (Fig. 3). 152 
Furthermore, RANK+ cells were also found in the single flattened or spindle ME cell layer 153 
located around normal ducts and alveoli with a diffuse staining pattern (Fig. 3). In RANK+ 154 
benign tumors, most LE and ME cells located in the inner and the outer cell layers, respectively, 155 
of neoplastic tubules were RANK+ cells showing a diffuse staining pattern. However, the 156 
apical/luminal staining pattern was also occasionally seen. Fusiform, polygonal, or round 157 
RANK+ ME cells formed fascicles without atypia in all RANK+ complex adenomas, and were 158 
also embedded in lacunae of cartilaginous matrix in 2 of 5 RANK+ benign mixed tumors (Fig. 159 
2). In malignant tumors, 4 staining patterns were observed. First, RANK+ ME cells were seen 160 
forming a single complete or incomplete layer of flattened or spindle cells located around 161 
neoplastic nodules, tubules, and papillae (Fig. 4). Second, RANK+ fusiform ME cells forming 162 
nests or fascicles were also seen in complex and mixed carcinomas. Third, RANK+ LE cells 163 
forming 1–3 layers of proliferating cells into the lumen of neoplastic tubules were observed in 164 
malignant tumors with either diffuse or apical/luminal RANK staining patterns (Fig. 4). And 165 
fourth, rounded cells of the cartilage nests observed in the mixed carcinoma were RANK0 and 166 
p63–. 167 
RANK protein expression was higher in animals ≥10 y old (p = 0.027; Table 3). RANK 168 
expression was not related to tumor size or histologic grade of the malignant tumors (Table 3). 169 
RANK gene expression level was similar in both normal ME and LE cell lines (CmME-170 
N1 and CmLE-N1, respectively). The tumor ME (CmME-T2, CmME-T3, CmME-K1, CmME-171 
K2) and LE (CmLE-T2, CmLE-T3) cell lines expressed RANK gene at levels similar to their 172 
respective controls from normal ME (CmME-N1; Fig. 5) and LE (CmLE-N1; Fig. 6) cell lines, 173 
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except for the CmLE-T1 cell line (from case 1, complex carcinoma) that expressed twice as 174 
much RANK as normal cells (Fig. 6). RANK expression was detected in most of the tissue 175 
samples and in all cell lines studied. ME and LE cells expressed RANK at a similar level in 176 
normal, dysplastic, and neoplastic canine mammary tissues and in primary cell lines. RANK 177 
protein labeling was found in ~75% of the tissue samples analyzed. We found no statistically 178 
significant differences in RANK protein expression between the histologic types: dysplasias 179 
(100%), malignant tumors (76%), normal glands (70%), and benign tumors (67%). This could be 180 
because of the high Ki67 proliferation index found in dysplasia (data not shown). In human 181 
breast tissue, a positive correlation between RANK expression and Ki67 labeling index has been 182 
reported.
1
 RANK+ malignant tumors are more common in dogs (76%) than are breast carcinomas 183 
in women (57% reported by some authors and 6% from others).
8,16
 Different methodologies to 184 
evaluate IHC findings could contribute to discrepancies among studies. When grouped by 185 
histologic subtypes, all tumor subtypes expressed RANK at a similar level. To our knowledge, 186 
there are no published reports of a correlation of RANK gene expression with histologic subtype 187 
(simple, complex, mixed) in breast cancer; however, there is one study in which RANK 188 
expression was independent of neoplasm subtype (ductal vs. lobular).
17
 All RANK+ cases, 189 
regardless of their histologic subtype, had a high percentage of RANK+ cells (≥67%). Sixty-five 190 
percent of RANK+ cells were reported in breast cancer
16
 according to our results (71% of 191 
RANK+ cells in malignant tumors), but there are no published data concerning other histologic 192 
types of samples.  193 
Double-labeling IHC was performed to analyze RANK labeling in the 2 epithelial cell 194 
populations of the mammary gland: ME and/or LE cells. After observing the cytoplasmic and/or 195 
apical/luminal RANK labeling pattern, we selected p63 as the marker of ME cells because of its 196 
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nuclear staining pattern.
5
 RANK protein expression was similar in both ME (57%) and LE (56%) 197 
cells, which corresponds with the observation of RANK protein in both compartments of murine 198 
mammary epithelial cells.
8
 A higher level of RANK protein expression was found in older 199 
animals (≥10 y, p = 0.027). Statistically significant differences between RANK protein 200 
expression and tumor size or histologic grade of malignancy were not observed in canine 201 
mammary glands. In human breast cancer, increased RANK expression was correlated with 202 
higher histologic grade of malignancy by IHC,
14
 and a higher RANK gene expression was 203 
observed in bigger tumors by microarray analysis.
17
 However, microarray analysis showed no 204 
correlation between age and RANK expression.
17
 Comparison between results from 2 different 205 
methodologies (IHC and microarray) may have intrinsic limitations. It is important to note that in 206 
human and murine mammary gland tumors, most authors report that high RANK level in 207 
primary tumors is predictive of poorer prognosis.
17
 Unfortunately, we do not possess available 208 
data concerning the biological behavior of the tumors included in our study to support this 209 
hypothesis. 210 
Transcript levels of RANK were shown by RT-qPCR to be similar between canine 211 
mammary normal ME versus LE cell lines, and between normal versus neoplastic cell lines, in 212 
accordance with IHC results. Only the CmLE-T1 cell line had higher RANK levels than the 213 
normal counterpart, which could be the result of the fact that the tumor had been classified as 214 
grade 3 malignancy, whereas the rest of the malignant tumors had been classified as grades 1 and 215 
2 (data not shown). In humans, studies on RANK gene expression by RT-qPCR in ME and/or LE 216 
cell lines from the breast have not been found, and those studies in neoplastic cell lines are 217 
contradictory. Thus, some authors have shown that higher RANK expression in breast cancer 218 
cells correlated with greater metastatic rates in bone,
2,20
 whereas other authors have shown that 219 
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transcript levels of RANK gene were reduced in tumor samples when compared with normal 220 
tissue, and that reduced RANK expression was associated with poor clinical outcomes, 221 
disseminated metastasis, bone metastasis, and death.
11
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Table 1. Clinical and pathologic features of dogs with mammary tumors used for isolation of 277 
myoepithelial (ME) and luminal epithelial (LE) cells. 278 
Case Breed 
Age 
(y) Sex 
Location 
of tumor 
Size of 
tumor 
(cm) 
Histologic 
classification 
of tumor 
ME cell 
line 
LE cell 
line 
1* Poodle 14 Female II right 0.9 Complex 
carcinoma 
CmME-T1 CmLE-T1 
2 Rottweiler 8 Female III left 0.4 Simple 
tubulopapillary 
carcinoma 
CmME-T2 CmLE-T2 
3 Shih Tzu 8 Female IV right 1 Benign mixed 
tumor 
CmME-T3 CmLE-T3 
* Fresh tissue sample from normal mammary gland (V right) of case 1 was also collected, named 279 
CmME-N1 and CmLE-N1 for the ME and LE cell lines obtained, respectively. 280 
281 
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Table 2. RANK protein expression in cases under study and the median percentage of 282 
myoepithelial (ME; p63+) and luminal epithelial (LE; p63–) cells expressing RANK antigen in 283 
different mammary tissues. 284 
Sample type 
No. 
of 
cases 
No. of 
RANK+ 
cases 
% of RANK+ 
cells in RANK+ 
cases 
% 
RANK+ 
ME cells
 
% 
RANK+ 
LE cells
 
Normal mammary tissue 17 12 (70) 93 54 66 
Dysplasia 4 4 (100) 80 59 60 
Benign tumor 9 6 (67) 76 46 42 
Simple adenoma 1 0 0 0 0 
Complex adenoma 2 1 (50) 67 42 60 
Benign mixed tumor 6 5 (83) 77 77 70 
Malignant tumor 17 13 (76) 71 67 57 
Simple carcinoma 5 4 (80) 68 76 58 
Complex carcinoma 9 8 (89) 69 68 66 
Mixed carcinoma 3 1 (33) 91 56 48 
Total 47 35 (74) 80 57 56 
Numbers in parentheses are percentages. 285 
286 
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Table 3. RANK protein expression and clinicopathologic parameters of the 26 dogs. 287 
Parameter/range No. of total cases No. of RANK+ cases 
Age*   
<10 y 6 1 (17) 
≥10 y 20 18 (90) 
Tumor size   
<2 cm 15 10 (67) 
≥2 cm 11 9 (82) 
Histologic grade of carcinoma   
1 9 6 (67) 
2 7 6 (86) 
3 1 1 (100) 
Numbers in parentheses are percentages. 288 
* p = 0.027 289 
290 
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Figure 1. Simple adenoma in a canine mammary gland; p63+ cells form a single complete or 291 
incomplete layer of flattened cells around neoplastic ducts and alveoli in a RANK– case. 292 
Double immunohistochemical labeling for RANK (red) and p63 (brown) (EnVision 293 
doublestain system, Dako). Bar = 20 µm. 294 
Figure 2. Benign mixed tumor in a canine mammary gland. In the lacunae of cartilaginous 295 
matrix, both RANK+/p63– cells (black arrows) and co-expression of RANK and p63 antigens 296 
are present in some cells (red arrow). Double immunohistochemical labeling for RANK (red) 297 
and p63 (brown; EnVision doublestain system, Dako). Bar = 20 µm. 298 
Figure 3. Dysplasia in a canine mammary gland. RANK labeling was observed in both p63– and 299 
p63+ cells. RANK+/p63– cells are present in the outer, proliferative, and luminal layers of 300 
neoplastic tubules (black arrows). Co-expression of RANK and p63 proteins is present in all 3 301 
cell layers of neoplastic tubules (red arrows). Double immunohistochemical labeling for 302 
RANK (red) and p63 (brown; EnVision doublestain system, Dako). Bar = 20 µm. 303 
Figure 4. Simple carcinoma in a canine mammary gland. Round-to-oval cells form the 304 
neoplastic nodules that histologically appeared to be of only one type. Double 305 
immunohistochemical labeling revealed 4 different cell types: 1) RANK+/p63– cells (black 306 
arrows); 2) RANK+/p63+ cells (red arrows); 3) RANK–/p63+ cells (black stars); and 4) 307 
RANK–/p63– cells (red stars). Double immunohistochemical labeling for RANK (red) and 308 
p63 (brown; EnVision doublestain system, Dako). Bar = 20 µm. 309 
Figure 5. RANK gene expression by RT-qPCR in canine mammary myoepithelial (CmME) cell 310 
lines. The fold increase of each specific mRNA was normalized with the normal ME cell line 311 
(CmME-N1), and the error bars indicate one standard deviation of experimental triplicates. 312 
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RANK gene expression level was similar in the neoplastic ME cell lines compared to the 313 
normal ME cell line.  314 
Figure 6. RANK gene expression by RT-qPCR in canine mammary luminal epithelial (CmLE) 315 
cell lines. The fold increase of each specific mRNA was normalized with the normal LE cell 316 
line (CmLE-N1), and the error bars indicate one standard deviation of experimental 317 
triplicates. The neoplastic LE cell lines expressed RANK at levels similar to the normal LE 318 
cell line; only the neoplastic CmLE-T1 cell line showed a 2-fold increase in RANK expression 319 
compared to the normal LE cell line. 320 
